Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial
Although interleukin-23 has been implicated in the pathogenesis of asthma, in this randomized, controlled trial involving adults with severe asthma, inhibition of interleukin-23 signaling with the monoclonal antibody risankizumab resulted in worse asthma outcomes than placebo.
Uložené v:
| Vydané v: | The New England journal of medicine Ročník 385; číslo 18; s. 1669 - 1679 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Boston
Massachusetts Medical Society
28.10.2021
Massachussetts Medical Society |
| Predmet: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Although interleukin-23 has been implicated in the pathogenesis of asthma, in this randomized, controlled trial involving adults with severe asthma, inhibition of interleukin-23 signaling with the monoclonal antibody risankizumab resulted in worse asthma outcomes than placebo. |
|---|---|
| AbstractList | Although interleukin-23 has been implicated in the pathogenesis of asthma, in this randomized, controlled trial involving adults with severe asthma, inhibition of interleukin-23 signaling with the monoclonal antibody risankizumab resulted in worse asthma outcomes than placebo. AbstractBackgroundInterleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear.MethodsWe conducted a phase 2a, multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group trial to assess the efficacy and safety of risankizumab, an anti–interleukin-23p19 monoclonal antibody, in adults with severe asthma. Patients were assigned to receive 90 mg of risankizumab or placebo, administered subcutaneously once every 4 weeks. The primary end point was the time to the first asthma worsening. Asthma worsening was defined as deterioration from baseline on 2 or more consecutive days; deterioration was considered to be a decrease of at least 30% in the morning peak expiratory flow or an increase from baseline of at least 50% in the number of puffs of rescue medication in a 24-hour period (equating to at least four additional puffs), a severe asthma exacerbation, or an increase of 0.75 or more points on the 5-item Asthma Control Questionnaire (ACQ-5; scores range from 0 to 6, with higher scores indicating less control). Secondary end points were the annualized rate of asthma worsening, the annualized rate of severe exacerbations, the ACQ-5 score, and the forced expiratory volume in 1 second. Exploratory end points were assessed with the use of sputum cytologic analysis and gene expression analysis, and safety was assessed.ResultsA total of 105 patients received risankizumab and 109 received placebo. The clinical characteristics of the patients were similar in the two groups. The time to the first asthma worsening was shorter with risankizumab than with placebo (median, 40 days vs. 86 days; hazard ratio, 1.46; 95% confidence interval [CI], 1.05 to 2.04; P=0.03). The rate ratio for annualized asthma worsening with risankizumab as compared with placebo was 1.49 (95% CI, 1.12 to 1.99), and the rate ratio for severe exacerbations was 1.13 (95% CI, 0.75 to 1.70). Sputum transcriptomic pathway analysis showed that genes involved in the activation of natural killer cells and cytotoxic T cells and the activation of the type 1 helper T and type 17 helper T transcription factors were down-regulated by risankizumab. No safety concerns were associated with risankizumab therapy.ConclusionsRisankizumab treatment was not beneficial in severe asthma. The time to the first asthma worsening was shorter and the annualized rate of asthma worsening was higher with risankizumab than with placebo. (Funded by AbbVie and Boehringer Ingelheim; ClinicalTrials.gov number, NCT02443298.) BACKGROUND: Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear. METHODS: We conducted a phase 2a, multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group trial to assess the efficacy and safety of risankizumab, an anti-interleukin-23p19 monoclonal antibody, in adults with severe asthma. Patients were assigned to receive 90 mg of risankizumab or placebo, administered subcutaneously once every 4 weeks. The primary end point was the time to the first asthma worsening. Asthma worsening was defined as deterioration from baseline on 2 or more consecutive days; deterioration was considered to be a decrease of at least 30% in the morning peak expiratory flow or an increase from baseline of at least 50% in the number of puffs of rescue medication in a 24-hour period (equating to at least four additional puffs), a severe asthma exacerbation, or an increase of 0.75 or more points on the 5-item Asthma Control Questionnaire (ACQ-5; scores range from 0 to 6, with higher scores indicating less control). Secondary end points were the annualized rate of asthma worsening, the annualized rate of severe exacerbations, the ACQ-5 score, and the forced expiratory volume in 1 second. Exploratory end points were assessed with the use of sputum cytologic analysis and gene expression analysis, and safety was assessed. RESULTS: A total of 105 patients received risankizumab and 109 received placebo. The clinical characteristics of the patients were similar in the two groups. The time to the first asthma worsening was shorter with risankizumab than with placebo (median, 40 days vs. 86 days; hazard ratio, 1.46; 95% confidence interval [CI], 1.05 to 2.04; P = 0.03). The rate ratio for annualized asthma worsening with risankizumab as compared with placebo was 1.49 (95% CI, 1.12 to 1.99), and the rate ratio for severe exacerbations was 1.13 (95% CI, 0.75 to 1.70). Sputum transcriptomic pathway analysis showed that genes involved in the activation of natural killer cells and cytotoxic T cells and the activation of the type 1 helper T and type 17 helper T transcription factors were down-regulated by risankizumab. No safety concerns were associated with risankizumab therapy. CONCLUSIONS: Risankizumab treatment was not beneficial in severe asthma. The time to the first asthma worsening was shorter and the annualized rate of asthma worsening was higher with risankizumab than with placebo. (Funded by AbbVie and Boehringer Ingelheim; ClinicalTrials.gov number, NCT02443298.). Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear.BACKGROUNDInterleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear.We conducted a phase 2a, multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group trial to assess the efficacy and safety of risankizumab, an anti-interleukin-23p19 monoclonal antibody, in adults with severe asthma. Patients were assigned to receive 90 mg of risankizumab or placebo, administered subcutaneously once every 4 weeks. The primary end point was the time to the first asthma worsening. Asthma worsening was defined as deterioration from baseline on 2 or more consecutive days; deterioration was considered to be a decrease of at least 30% in the morning peak expiratory flow or an increase from baseline of at least 50% in the number of puffs of rescue medication in a 24-hour period (equating to at least four additional puffs), a severe asthma exacerbation, or an increase of 0.75 or more points on the 5-item Asthma Control Questionnaire (ACQ-5; scores range from 0 to 6, with higher scores indicating less control). Secondary end points were the annualized rate of asthma worsening, the annualized rate of severe exacerbations, the ACQ-5 score, and the forced expiratory volume in 1 second. Exploratory end points were assessed with the use of sputum cytologic analysis and gene expression analysis, and safety was assessed.METHODSWe conducted a phase 2a, multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group trial to assess the efficacy and safety of risankizumab, an anti-interleukin-23p19 monoclonal antibody, in adults with severe asthma. Patients were assigned to receive 90 mg of risankizumab or placebo, administered subcutaneously once every 4 weeks. The primary end point was the time to the first asthma worsening. Asthma worsening was defined as deterioration from baseline on 2 or more consecutive days; deterioration was considered to be a decrease of at least 30% in the morning peak expiratory flow or an increase from baseline of at least 50% in the number of puffs of rescue medication in a 24-hour period (equating to at least four additional puffs), a severe asthma exacerbation, or an increase of 0.75 or more points on the 5-item Asthma Control Questionnaire (ACQ-5; scores range from 0 to 6, with higher scores indicating less control). Secondary end points were the annualized rate of asthma worsening, the annualized rate of severe exacerbations, the ACQ-5 score, and the forced expiratory volume in 1 second. Exploratory end points were assessed with the use of sputum cytologic analysis and gene expression analysis, and safety was assessed.A total of 105 patients received risankizumab and 109 received placebo. The clinical characteristics of the patients were similar in the two groups. The time to the first asthma worsening was shorter with risankizumab than with placebo (median, 40 days vs. 86 days; hazard ratio, 1.46; 95% confidence interval [CI], 1.05 to 2.04; P = 0.03). The rate ratio for annualized asthma worsening with risankizumab as compared with placebo was 1.49 (95% CI, 1.12 to 1.99), and the rate ratio for severe exacerbations was 1.13 (95% CI, 0.75 to 1.70). Sputum transcriptomic pathway analysis showed that genes involved in the activation of natural killer cells and cytotoxic T cells and the activation of the type 1 helper T and type 17 helper T transcription factors were down-regulated by risankizumab. No safety concerns were associated with risankizumab therapy.RESULTSA total of 105 patients received risankizumab and 109 received placebo. The clinical characteristics of the patients were similar in the two groups. The time to the first asthma worsening was shorter with risankizumab than with placebo (median, 40 days vs. 86 days; hazard ratio, 1.46; 95% confidence interval [CI], 1.05 to 2.04; P = 0.03). The rate ratio for annualized asthma worsening with risankizumab as compared with placebo was 1.49 (95% CI, 1.12 to 1.99), and the rate ratio for severe exacerbations was 1.13 (95% CI, 0.75 to 1.70). Sputum transcriptomic pathway analysis showed that genes involved in the activation of natural killer cells and cytotoxic T cells and the activation of the type 1 helper T and type 17 helper T transcription factors were down-regulated by risankizumab. No safety concerns were associated with risankizumab therapy.Risankizumab treatment was not beneficial in severe asthma. The time to the first asthma worsening was shorter and the annualized rate of asthma worsening was higher with risankizumab than with placebo. (Funded by AbbVie and Boehringer Ingelheim; ClinicalTrials.gov number, NCT02443298.).CONCLUSIONSRisankizumab treatment was not beneficial in severe asthma. The time to the first asthma worsening was shorter and the annualized rate of asthma worsening was higher with risankizumab than with placebo. (Funded by AbbVie and Boehringer Ingelheim; ClinicalTrials.gov number, NCT02443298.). |
| Author | Cousins, David J Nair, Parameswaran Brightling, Christopher E Louis, Renaud Singh, Dave |
| Author_xml | – sequence: 1 givenname: Christopher E surname: Brightling fullname: Brightling, Christopher E organization: From the Institute for Lung Health, Leicester NIHR Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester (C.E.B., D.J.C.), and the University of Manchester, Manchester University NHS Foundation Trust, Manchester (D.S.) — both in the United Kingdom; the Firestone Institute for Respiratory Health, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada (P.N.); and the GIGA-I3 Research Unit, University of Liege, Department of Pneumology, Centre Hospitalier Universitaire Liège, Liege, Belgium (R.L.) – sequence: 2 givenname: Parameswaran surname: Nair fullname: Nair, Parameswaran organization: From the Institute for Lung Health, Leicester NIHR Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester (C.E.B., D.J.C.), and the University of Manchester, Manchester University NHS Foundation Trust, Manchester (D.S.) — both in the United Kingdom; the Firestone Institute for Respiratory Health, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada (P.N.); and the GIGA-I3 Research Unit, University of Liege, Department of Pneumology, Centre Hospitalier Universitaire Liège, Liege, Belgium (R.L.) – sequence: 3 givenname: David J orcidid: 0000-0003-3821-9596 surname: Cousins fullname: Cousins, David J organization: From the Institute for Lung Health, Leicester NIHR Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester (C.E.B., D.J.C.), and the University of Manchester, Manchester University NHS Foundation Trust, Manchester (D.S.) — both in the United Kingdom; the Firestone Institute for Respiratory Health, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada (P.N.); and the GIGA-I3 Research Unit, University of Liege, Department of Pneumology, Centre Hospitalier Universitaire Liège, Liege, Belgium (R.L.) – sequence: 4 givenname: Renaud surname: Louis fullname: Louis, Renaud organization: From the Institute for Lung Health, Leicester NIHR Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester (C.E.B., D.J.C.), and the University of Manchester, Manchester University NHS Foundation Trust, Manchester (D.S.) — both in the United Kingdom; the Firestone Institute for Respiratory Health, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada (P.N.); and the GIGA-I3 Research Unit, University of Liege, Department of Pneumology, Centre Hospitalier Universitaire Liège, Liege, Belgium (R.L.) – sequence: 5 givenname: Dave surname: Singh fullname: Singh, Dave organization: From the Institute for Lung Health, Leicester NIHR Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester (C.E.B., D.J.C.), and the University of Manchester, Manchester University NHS Foundation Trust, Manchester (D.S.) — both in the United Kingdom; the Firestone Institute for Respiratory Health, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada (P.N.); and the GIGA-I3 Research Unit, University of Liege, Department of Pneumology, Centre Hospitalier Universitaire Liège, Liege, Belgium (R.L.) |
| BookMark | eNp1kc1u1DAQgC1URLeFI3dLCIkDAXucxM5xtWr5UYEKytmaOJPWixMXO6kEJx6CJ-RJ2CUIBFLnMnP4vtH8HLGDMY7E2EMpnklR1c_fnrx-ExGEEsaIO2wlK6WKshT1AVsJAaYodaMO2VHOW7ELWTb32KEqtailhhU7fe8zjp_813nAlvuRf6AbSsTXeboakP_49p2v-fkVZuKAT_l5QEdtLDZxnFIMgTp-kTyG--xujyHTg9_5mH08PbnYvCzO3r14tVmfFU5pmIoSwFW1AwVAStei073QqIRu2t4QVpoIQXdI0PWNajvXyro2IKumaaXWpI6ZWvoGT5dkY2q9vQEb0S_1HC4tOtuSBaiNBdMobXbWk8W6TvHzTHmyg8-OQsCR4pwtVEbrqhS63KGP_kO3cU7jbqdflJSyqvdUsVAuxZwT9fY6-QHTFyuF3b_F_vOWv2P_4Z2fcPL7K6IPt1qPF2sYsh1pO9zC_QT3qpm9 |
| CitedBy_id | crossref_primary_10_1016_j_coi_2024_102494 crossref_primary_10_1186_s12929_025_01142_w crossref_primary_10_1080_17476348_2022_2045197 crossref_primary_10_3389_fmed_2022_921967 crossref_primary_10_1016_j_jaci_2023_05_023 crossref_primary_10_1186_s13052_025_02068_7 crossref_primary_10_1016_j_cytogfr_2024_05_001 crossref_primary_10_3390_ijms24087581 crossref_primary_10_1016_j_resinv_2024_11_015 crossref_primary_10_1165_rcmb_2024_0180ED crossref_primary_10_1016_j_anai_2024_03_012 crossref_primary_10_2147_JIR_S512605 crossref_primary_10_1080_14712598_2022_2160238 crossref_primary_10_1183_20734735_0212_2022 crossref_primary_10_1016_j_jacig_2022_08_003 crossref_primary_10_1093_rheumatology_keac071 crossref_primary_10_1016_j_jaci_2022_10_007 crossref_primary_10_2500_aap_2022_43_220047 crossref_primary_10_1038_s41467_024_53038_2 crossref_primary_10_1007_s10405_022_00438_0 crossref_primary_10_1111_resp_14520 crossref_primary_10_26442_20751753_2024_3_202658 crossref_primary_10_1016_j_jaci_2022_08_009 crossref_primary_10_3390_cells14060400 crossref_primary_10_3389_fimmu_2024_1498288 crossref_primary_10_3390_ijms232214466 crossref_primary_10_1007_s11882_024_01153_x crossref_primary_10_3389_fped_2022_837667 crossref_primary_10_3390_jcm14165641 crossref_primary_10_1016_j_jaci_2022_04_024 crossref_primary_10_3390_cells13050384 crossref_primary_10_1002_ctm2_816 crossref_primary_10_1016_j_jaci_2022_06_010 crossref_primary_10_1007_s15033_022_3449_1 crossref_primary_10_1111_imr_70007 crossref_primary_10_63845_mdmgea08 crossref_primary_10_1016_j_pupt_2025_102347 crossref_primary_10_1183_16000617_0193_2022 crossref_primary_10_2147_JAA_S496630 crossref_primary_10_1016_j_pharmthera_2023_108551 crossref_primary_10_3389_fimmu_2023_1149203 crossref_primary_10_1016_j_iac_2022_04_005 crossref_primary_10_1016_j_intimp_2024_112189 crossref_primary_10_1080_1744666X_2023_2125380 crossref_primary_10_1055_a_2249_2207 crossref_primary_10_1111_all_15679 crossref_primary_10_3390_ph17121651 crossref_primary_10_1055_a_1990_2341 crossref_primary_10_3390_biomedicines10051064 crossref_primary_10_1080_14712598_2022_2132143 crossref_primary_10_1016_j_banm_2023_02_006 crossref_primary_10_1016_j_anai_2022_01_024 crossref_primary_10_1001_jama_2024_22684 crossref_primary_10_1016_j_phymed_2024_156090 crossref_primary_10_3390_biomedicines10010113 crossref_primary_10_4168_aair_2022_14_1_1 crossref_primary_10_3389_fimmu_2022_974066 crossref_primary_10_1016_j_phrs_2023_106658 crossref_primary_10_1038_s41598_025_06122_6 crossref_primary_10_1056_NEJMe2114472 crossref_primary_10_1038_s41577_025_01159_0 crossref_primary_10_3390_jcm12185846 crossref_primary_10_1016_j_anai_2022_07_027 crossref_primary_10_1080_02770903_2024_2395383 crossref_primary_10_1016_j_jaci_2025_03_025 crossref_primary_10_1016_j_jaci_2021_12_769 crossref_primary_10_1016_j_iac_2024_07_008 crossref_primary_10_3389_fimmu_2023_1132939 crossref_primary_10_1007_s12016_024_09012_3 crossref_primary_10_1080_17476348_2022_2096593 crossref_primary_10_1016_j_jaip_2021_12_007 crossref_primary_10_1056_NEJMra2032506 crossref_primary_10_1126_scitranslmed_ado6649 crossref_primary_10_1002_alr_23268 crossref_primary_10_1016_j_pccm_2025_08_003 crossref_primary_10_3390_jcm13226991 crossref_primary_10_1183_23120541_00653_2022 crossref_primary_10_1183_13993003_00826_2023 crossref_primary_10_1165_rcmb_2023_0424OC crossref_primary_10_3390_jcm13123474 |
| Cites_doi | 10.1056/NEJMoa1607017 10.1007/s40265-019-01136-7 10.1111/cea.13086 10.1183/09031936.00202013 10.1111/resp.12299 10.1016/S0140-6736(17)30570-6 10.1016/S0140-6736(18)31713-6 10.1378/chest.09-3058 10.1002/JLB.MR0718-269R 10.1016/S0140-6736(17)33311-1 10.1016/j.jaci.2019.03.027 10.1016/j.jaci.2018.05.026 10.1164/ajrccm.164.1.2008060 10.1164/ajrccm.160.3.9812110 10.1016/j.jaip.2015.03.017 10.1126/scitranslmed.aab3142 10.1002/eji.200738051 10.1164/rccm.200711-1754OC 10.1159/000336418 10.1016/j.jaci.2009.02.024 10.1038/ni.1627 10.1016/S1074-7613(00)00070-4 10.1164/rccm.201311-2011LE 10.1016/j.jaci.2018.11.042 10.1016/j.jaci.2013.10.011 10.1164/rccm.200801-086OC 10.1164/rccm.201208-1470OC 10.4049/jimmunol.168.11.5699 |
| ContentType | Journal Article |
| Contributor | GIGA I3-Cellular and Molecular Immunology - ULiège |
| Contributor_xml | – sequence: 1 fullname: GIGA I3-Cellular and Molecular Immunology - ULiège |
| Copyright | Copyright © 2021 Massachusetts Medical Society. All rights reserved. Copyright © 2021 Massachusetts Medical Society. |
| Copyright_xml | – notice: Copyright © 2021 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2021 Massachusetts Medical Society. |
| DBID | AAYXX CITATION 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 Q33 |
| DOI | 10.1056/NEJMoa2030880 |
| DatabaseName | CrossRef Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database (Proquest) ProQuest Central Essentials - QC Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Collection (ProQuest) New England Journal of Medicine ProQuest Biological Science Collection Consumer Health Database Healthcare Administration Database (ProQuest) Medical Database Psychology Database Research Library (ProQuest) Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Université de Liège - Open Repository and Bibliography (ORBI) |
| DatabaseTitle | CrossRef ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 1679 |
| ExternalDocumentID | oai_orbi_ulg_ac_be_2268_289378 10_1056_NEJMoa2030880 NJ202110283851807 |
| Genre | Original Article |
| GrantInformation | Boehringer Ingelheim |
| GroupedDBID | - 0R 0WA 123 1VV 2KS 2WC 34G 39C 4 4.4 53G 55 5RE 7FN 7RV 85S 9M8 AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAUTI AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACPVT ACRZS ADBBV ADBIT ADCBC AENEX AETEA AFFNX AFHKK AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BES BHPHI BLC C45 CJ0 CO CS3 DCD DU5 DZ EBS ET EX3 F5P FD8 FM. GJ HCIFZ HZ I4R IH2 K-O KM KOO L7B M2O M2P M7P MQT MVM N9A NEJ O9- OK1 OMK OVD P-O P-S P2P QJJ RHI RWL RXW S10 S6N SJN TAE TAF TEORI TN5 TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 29N 36B 7X7 8AO 8C1 8FE 8FH 8FI AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ABUFD ABUWG ACKOT ACPFK ADRHT ADUKH AERZD AFFHD AFKRA AGHSJ AN0 AQUVI AZQEC BCU BKEYQ BKNYI BNQBC BPHCQ BVXVI BYPQX CCPQU CITATION DWQXO FYUFA GNUQQ GUQSH HF~ HMCUK HZ~ LK8 M0R M0T M1P M2M N4W NAPCQ PCD PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PSYQQ SJFOW TUQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM 7XB BEC K0Y MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO Q33 |
| ID | FETCH-LOGICAL-c372t-422c56c2322e3760d7f07a3079bf8ea57eea27dae2df93bdcb166821599b177e3 |
| IEDL.DBID | M2P |
| ISICitedReferencesCount | 89 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000711605500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Sat Nov 29 01:28:58 EST 2025 Fri Sep 05 07:52:52 EDT 2025 Sat Nov 29 14:43:37 EST 2025 Sat Nov 29 07:50:01 EST 2025 Tue Nov 18 21:53:07 EST 2025 Tue Dec 21 14:38:58 EST 2021 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 18 |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c372t-422c56c2322e3760d7f07a3079bf8ea57eea27dae2df93bdcb166821599b177e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 scopus-id:2-s2.0-85118445608 |
| ORCID | 0000-0003-3821-9596 |
| PMID | 34706172 |
| PQID | 2587111564 |
| PQPubID | 40644 |
| PageCount | 11 |
| ParticipantIDs | liege_orbi_v2_oai_orbi_ulg_ac_be_2268_289378 proquest_miscellaneous_2587754074 proquest_journals_2587111564 crossref_primary_10_1056_NEJMoa2030880 crossref_citationtrail_10_1056_NEJMoa2030880 mms_nejm_10_1056_NEJMoa2030880 |
| PublicationCentury | 2000 |
| PublicationDate | 20211028 2021-10-28 |
| PublicationDateYYYYMMDD | 2021-10-28 |
| PublicationDate_xml | – month: 10 year: 2021 text: 20211028 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | Boston |
| PublicationPlace_xml | – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationYear | 2021 |
| Publisher | Massachusetts Medical Society Massachussetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society – name: Massachussetts Medical Society |
| References | r2 Choy, DF, Hart, KM, Borthwick, LA (r23) 2015; 7 Chung, KF, Wenzel, SE, Brozek, JL (r3) 2014; 43 Feagan, BG, Sandborn, WJ, D’Haens, G (r16) 2017; 389 Prager, I, Watzl, C (r25) 2019; 105 Schatz, M, Zeiger, RS, Yang, S-J (r18) 2015; 3 Haldar, P, Pavord, ID, Shaw, DE (r5) 2008; 178 Doe, C, Bafadhel, M, Siddiqui, S (r11) 2010; 138 Wakashin, H, Hirose, K, Maezawa, Y (r13) 2008; 178 McKeage, K, Duggan, S (r22) 2019; 79 Wenzel, SE, Schwartz, LB, Langmack, EL (r6) 1999; 160 Papp, KA, Blauvelt, A, Bukhalo, M (r17) 2017; 376 Kanda, N, Watanabe, S (r21) 2008; 38 Desai, D, Newby, C, Symon, FA (r19) 2013; 188 Östling, J, van Geest, M, Schofield, JPR (r28) 2019; 144 Jevnikar, Z, Östling, J, Ax, E (r29) 2019; 143 Haworth, O, Cernadas, M, Yang, R, Serhan, CN, Levy, BD (r14) 2008; 9 Oppmann, B, Lesley, R, Blom, B (r9) 2000; 13 Laporte, JC, Moore, PE, Baraldo, S (r24) 2001; 164 Ciprandi, G, Cuppari, C, Salpietro, AM (r10) 2012; 159 Parham, C, Chirica, M, Timans, J (r27) 2002; 168 Papi, A, Brightling, C, Pedersen, SE, Reddel, HK (r1) 2018; 391 Al-Ramli, W, Préfontaine, D, Chouiali, F (r12) 2009; 123 Li, Y, Hua, S (r8) 2014; 19 Gordon, KB, Strober, B, Lebwohl, M (r15) 2018; 392 Marijsse, GS, Seys, SF, Schelpe, A-S (r20) 2014; 189 Moore, WC, Hastie, AT, Li, X (r7) 2014; 133 Diver, S, Russell, RJ, Brightling, CE (r4) 2018; 48 Visvanathan, S, Baum, P, Vinisko, R (r26) 2019; 143 e_1_3_5_28_2 e_1_3_5_27_2 e_1_3_5_26_2 e_1_3_5_25_2 e_1_3_5_24_2 e_1_3_5_23_2 e_1_3_5_22_2 e_1_3_5_21_2 e_1_3_5_29_2 e_1_3_5_2_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_7_2 e_1_3_5_9_2 e_1_3_5_4_2 e_1_3_5_3_2 e_1_3_5_6_2 e_1_3_5_5_2 e_1_3_5_17_2 e_1_3_5_16_2 e_1_3_5_15_2 e_1_3_5_14_2 e_1_3_5_12_2 e_1_3_5_13_2 e_1_3_5_10_2 e_1_3_5_11_2 e_1_3_5_19_2 e_1_3_5_18_2 e_1_3_5_30_2 |
| References_xml | – volume: 79 start-page: 893 year: 2019 end-page: 900 ident: r22 article-title: Risankizumab: first global approval. publication-title: Drugs – volume: 48 start-page: 241 year: 2018 end-page: 252 ident: r4 article-title: New and emerging drug treatments for severe asthma. publication-title: Clin Exp Allergy – volume: 168 start-page: 5699 year: 2002 end-page: 5708 ident: r27 article-title: A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. publication-title: J Immunol – volume: 19 start-page: 663 year: 2014 end-page: 669 ident: r8 article-title: Mechanisms of pathogenesis in allergic asthma: role of interleukin-23. publication-title: Respirology – volume: 138 start-page: 1140 year: 2010 end-page: 1147 ident: r11 article-title: Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. publication-title: Chest – volume: 159 start-page: 183 year: 2012 end-page: 186 ident: r10 article-title: Serum IL-23 strongly and inversely correlates with FEV in asthmatic children. publication-title: Int Arch Allergy Immunol – volume: 391 start-page: 783 year: 2018 end-page: 800 ident: r1 article-title: Asthma. publication-title: Lancet – volume: 392 start-page: 650 year: 2018 end-page: 661 ident: r15 article-title: Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. publication-title: Lancet – volume: 178 start-page: 218 year: 2008 end-page: 224 ident: r5 article-title: Cluster analysis and clinical asthma phenotypes. publication-title: Am J Respir Crit Care Med – volume: 189 start-page: 1284 year: 2014 end-page: 1285 ident: r20 article-title: Obese individuals with asthma preferentially have a high IL-5/IL-17A/IL-25 sputum inflammatory pattern. publication-title: Am J Respir Crit Care Med – volume: 43 start-page: 343 year: 2014 end-page: 373 ident: r3 article-title: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. publication-title: Eur Respir J – volume: 123 start-page: 1185 year: 2009 end-page: 1187 ident: r12 article-title: T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. publication-title: J Allergy Clin Immunol – volume: 105 start-page: 1319 year: 2019 end-page: 1329 ident: r25 article-title: Mechanisms of natural killer cell-mediated cellular cytotoxicity. publication-title: J Leukoc Biol – volume: 389 start-page: 1699 year: 2017 end-page: 1709 ident: r16 article-title: Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. publication-title: Lancet – volume: 9 start-page: 873 year: 2008 end-page: 879 ident: r14 article-title: Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. publication-title: Nat Immunol – volume: 188 start-page: 657 year: 2013 end-page: 663 ident: r19 article-title: Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma. publication-title: Am J Respir Crit Care Med – volume: 133 start-page: 1557 issue: 6 year: 2014 end-page: 1563.e5 ident: r7 article-title: Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. publication-title: J Allergy Clin Immunol – volume: 143 start-page: 577 year: 2019 end-page: 590 ident: r29 article-title: Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. publication-title: J Allergy Clin Immunol – volume: 178 start-page: 1023 year: 2008 end-page: 1032 ident: r13 article-title: IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. publication-title: Am J Respir Crit Care Med – volume: 13 start-page: 715 year: 2000 end-page: 725 ident: r9 article-title: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. publication-title: Immunity – volume: 7 start-page: 301ra129 year: 2015 end-page: 301ra129 ident: r23 article-title: TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. publication-title: Sci Transl Med – volume: 160 start-page: 1001 year: 1999 end-page: 1008 ident: r6 article-title: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. publication-title: Am J Respir Crit Care Med – volume: 376 start-page: 1551 year: 2017 end-page: 1560 ident: r17 article-title: Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. publication-title: N Engl J Med – volume: 143 start-page: 2158 year: 2019 end-page: 2169 ident: r26 article-title: Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. publication-title: J Allergy Clin Immunol – volume: 3 start-page: 560 issue: 4 year: 2015 end-page: 565.e1 ident: r18 article-title: Prospective study on the relationship of obesity to asthma impairment and risk. publication-title: J Allergy Clin Immunol Pract – volume: 38 start-page: 1287 year: 2008 end-page: 1296 ident: r21 article-title: IL-12, IL-23, and IL-27 enhance human β-defensin-2 production in human keratinocytes. publication-title: Eur J Immunol – volume: 164 start-page: 141 year: 2001 end-page: 148 ident: r24 article-title: Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. publication-title: Am J Respir Crit Care Med – volume: 144 start-page: 1198 year: 2019 end-page: 1213 ident: r28 article-title: IL-17-high asthma with features of a psoriasis immunophenotype. publication-title: J Allergy Clin Immunol – ident: r2 article-title: (https://ginasthma.org/) – ident: e_1_3_5_18_2 doi: 10.1056/NEJMoa1607017 – ident: e_1_3_5_23_2 doi: 10.1007/s40265-019-01136-7 – ident: e_1_3_5_3_2 – ident: e_1_3_5_5_2 doi: 10.1111/cea.13086 – ident: e_1_3_5_4_2 doi: 10.1183/09031936.00202013 – ident: e_1_3_5_9_2 doi: 10.1111/resp.12299 – ident: e_1_3_5_17_2 doi: 10.1016/S0140-6736(17)30570-6 – ident: e_1_3_5_16_2 doi: 10.1016/S0140-6736(18)31713-6 – ident: e_1_3_5_12_2 doi: 10.1378/chest.09-3058 – ident: e_1_3_5_26_2 doi: 10.1002/JLB.MR0718-269R – ident: e_1_3_5_2_2 doi: 10.1016/S0140-6736(17)33311-1 – ident: e_1_3_5_29_2 doi: 10.1016/j.jaci.2019.03.027 – ident: e_1_3_5_30_2 doi: 10.1016/j.jaci.2018.05.026 – ident: e_1_3_5_25_2 doi: 10.1164/ajrccm.164.1.2008060 – ident: e_1_3_5_7_2 doi: 10.1164/ajrccm.160.3.9812110 – ident: e_1_3_5_19_2 doi: 10.1016/j.jaip.2015.03.017 – ident: e_1_3_5_24_2 doi: 10.1126/scitranslmed.aab3142 – ident: e_1_3_5_22_2 doi: 10.1002/eji.200738051 – ident: e_1_3_5_6_2 doi: 10.1164/rccm.200711-1754OC – ident: e_1_3_5_11_2 doi: 10.1159/000336418 – ident: e_1_3_5_13_2 doi: 10.1016/j.jaci.2009.02.024 – ident: e_1_3_5_15_2 doi: 10.1038/ni.1627 – ident: e_1_3_5_10_2 doi: 10.1016/S1074-7613(00)00070-4 – ident: e_1_3_5_21_2 doi: 10.1164/rccm.201311-2011LE – ident: e_1_3_5_27_2 doi: 10.1016/j.jaci.2018.11.042 – ident: e_1_3_5_8_2 doi: 10.1016/j.jaci.2013.10.011 – ident: e_1_3_5_14_2 doi: 10.1164/rccm.200801-086OC – ident: e_1_3_5_20_2 doi: 10.1164/rccm.201208-1470OC – ident: e_1_3_5_28_2 doi: 10.4049/jimmunol.168.11.5699 |
| SSID | ssj0000149 |
| Score | 2.623878 |
| Snippet | Although interleukin-23 has been implicated in the pathogenesis of asthma, in this randomized, controlled trial involving adults with severe asthma, inhibition... AbstractBackgroundInterleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23... Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment... BACKGROUND: Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the... |
| SourceID | liege proquest crossref mms |
| SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1669 |
| SubjectTerms | Adult Aged Allergy Anti-Asthmatic Agents Anti-Asthmatic Agents/adverse effects Anti-Asthmatic Agents/therapeutic use Antibodies, Monoclonal Antibodies, Monoclonal/adverse effects Antibodies, Monoclonal/therapeutic use Asthma Asthma/drug therapy Bronchoscopy Cell activation Clinical trials Critical Care Cytokines Cytotoxicity Disease control Disease Progression Double-Blind Method Double-blind studies Female Forced Expiratory Volume Forced Expiratory Volume/drug effects Gene expression General & internal medicine General Medicine Glucocorticoids Glucocorticoids/therapeutic use Human health sciences Humans Immunology Inflammation Interleukin 23 Interleukin-23 Subunit p19 Interleukin-23 Subunit p19/antagonists & inhibitors Lymphocytes T Male Medicine (all) Middle Aged Monoclonal antibodies Médecine générale & interne Natural killer cells Neutrophils Patients Placebos Pulmonary Respiratory tract Respiratory tract diseases risankizumab Safety Sciences de la santé humaine Sputum Statistical analysis Transcription activation Transcription factors Treatment Failure |
| SubjectTermsDisplay | Allergy/Immunology Asthma Pulmonary/Critical Care |
| SummonAdditionalLinks | – databaseName: New England Journal of Medicine Current dbid: DCD link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEB5VLUJcKE8RWqpFQpxiNVmvd9fHKCXiQhVBkXpb7WNMDbGN4qQHTvyI_sL-EnYcp6KqKsTNktcP7cx4vnn4G4B3GEbBCemTPBMyEVL4RAdZJDLlWgqdjsdu1A2bUKen-vw8n-_A8fZfmBq_V10BnyyaMtDb6fDHNBu-sZz4VXSM0fdI10iNT6Ynf_FF9Xi3Txn1pJp3Lr_lhPYWVJ6OvqWq2jtf5M7NzPb_-wWfwOMeUbLJRgWewg7Wz-Dhp75m_hxmn8vW1j_KX-vKOlbW7AtG9UU2aVcXlWXXv6_YhM0vojdj3A7ZnPLqrkmmmx72BQZ2Rkr6Ar7OPpxNPyb99ITEp4qvEsG5z6SPiIkjdb4EVYyUjSadu0KjzRSi5SpY5KHIUxe8G0upIwLIc6KkwvQl7NZNja-AUS2wiOEmKoki99Ypb6VQQQV02sswgOF2O43vqcVpwsXCdCXuTJpbezOA9zfLf244Ne5bOOxkY5qlK80lN8SF3R2vF9-M9cahifBRG06oSw_gKIrQkITuu9_hVrqmN9XW8CzGjGPizBnA25vT0ciocmJrbNabNYqoCsXrfz3jAB5xanuJ7o3rQ9hdLdf4Bh74y1XZLo86df0DIhjiNA priority: 102 providerName: Massachusetts Medical Society |
| Title | Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa2030880 https://www.proquest.com/docview/2587111564 https://www.proquest.com/docview/2587754074 https://orbi.uliege.be/handle/2268/289378 |
| Volume | 385 |
| WOSCitedRecordID | wos000711605500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBGY databaseName: New England Journal of Medicine Current customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250911 omitProxy: false ssIdentifier: ssj0000149 issn: 1533-4406 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nj9MwELXYLUJc-EYUlspIiFOjbZzEdk6odLfi0hKVgnqz_BU20CZL0-6BEz-CX8gvweO6yyK0XLg8JbIVRRnb8zIzeoPQS2sGRqVUR3mW0iilqY64oWVEE8JpypM4VgPfbIJNp3yxyIsQcGtDWeX-TPQHtWk0xMiPSeaofQzSJq_Pv0bQNQqyq6GFxgHquKEYSrompLgiHxXob4ggBY1N5_OPodN8IwmotYAi5BWf1FlCttq5mtWq_euA9l5nfPd_3_ceuhP4Jh7uFsh9dMPWD9CtScioP0TjWdXK-kv1bbuSClc1fm_d4rZ42G7OVhL__P4DD3Fx5nwdJrKPC4i6qyYa7Srcl9bgOSzhR-jD-HQ-ehuF3gqRThjZRCkhOqPa8SlioS7GsHLApNvwuSq5lRmzVhJmpCWmzBNltIop5Y4f5DkIVtnkMTqsm9o-QRgyhaX7GbWM2jTXUjEtacoMM1ZxTU0X9fdfV-ggPA79L5bCJ8AzKv4wRhe9upx-vlPcuG5i35tKNGtViQsiQCnbX2-Xn4TUQlnhyCUXBDgZ76Kes6io7efVdc872ltShI3cit9m7KIXl8NuC0JeRda22e7mMBAyTJ_--xHP0G0CJTHO9RF-hA436619jm7qi03VrnvogM0-Ai6YR-6Qj-Ie6rw5nRYzd3cyOnE4Gcw8zgHJxOM7jwUgK34BgFH9ng |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6VFgEX_hELpRgJOG3UXcexkwNCq8KqVdvVChapN9d_oYFNUja7RXDiIXgOHoonwZNNShEqtx64RYplKfE3M589428Anjrbs5pxEyQR4wHjzASx5WnAQxpzFof9vu7VzSbEaBQfHCTjFfjR3oXBssrWJ9aO2pYGz8g3aeSpfR-lTV4efwqwaxRmV9sWGktY7Lovn_2WrXqx88qv7zNKh68nW9tB01UgMKGg84BRaiJuPJOgDitCrEh7QnmoJzqNnYqEc4oKqxy1aRJqa3Sf89hHxiRBqSYX-nkvwRpDZTEsFaTjM3JVDd1uTqwaTU_PMTaxs32pKKrDoALlmRi4NsXsuA9teV79FRDqKDe88b_9n5twveHTZLA0gFuw4orbcGW_qRi4A8M3WaWKj9nXRa40yQry1nnjdWRQzY9yRX5--04GZHzkYzmhqkvGmFXQZbC1rOCfOksmaKJ34d2FfMU9WC3Kwt0HgpnQ1G-2neCOJUZpYRRnwgrrdGy47UC3XU1pGmF17O8xlXWCP-Lyj8XvwPPT4cdLRZHzBnZraMhypjN5QiUqgdfPi-l7qYzUTnryHEuKnDPuwIZHkCzch_y8-dZb5MjGUVXyN2w68OT0tXcxmDdShSsXyzEChRrZg39P8Riubk_29-Tezmj3IVyjWP7jwzyN12F1Plu4R3DZnMyzarZR2w2Bw4sG4i8uXU-E |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwELZKiyou_FcslGIk4LTR7jqJ7RwQWrWsqEpXq1Kk3ox_JjSwScpmtwhOPARPw-PwJHiSbClC5dYDt0ixLCX-ZuazZ_wNIU_A9Z2JuA2SOOJBxCMbSMfTgIdM8kiGg4Hp180mxHgsj46SyQr5sbwLg2WVS59YO2pXWjwj77HYU_sBSpv00rYsYrIzenHyKcAOUphpXbbTaCCyB18---1b9Xx3x6_1U8ZGLw-3XwVth4HAhoLNg4gxG3PrWQUDrA5xIu0L7WGfmFSCjgWAZsJpYC5NQuOsGXAufZRMEpRtgtDPe4WsiShmqNu_3z84J13VUu_29KrV9_R8o4dd7kvNUCkG1SjPxcO1KWbKfZjL8-qv4FBHvNGN__lf3STXW55Nh41h3CIrUNwm6_ttJcEdMjrIKl18zL4ucm1oVtA34I0a6LCaH-ea_vz2nQ7p5NjHeMp0l04w22DKYLup7J-Co4dounfJ20v5ig2yWpQF3CMUM6Sp34SD4BAlVhthNY-EEw6MtNx1SHe5ssq2guvY92Oq6sR_zNUfQOiQZ2fDTxqlkYsGdmuYqHJmMnXKFCqE18-L6XulrTKgPKmWiiEXlR2y5dGkCviQXzTf5hJFqnVglfoNoQ55fPbaux7MJ-kCykUzRqCAY3T_31M8Iusef-r17njvAbnGsCrIR38mN8nqfLaAh-SqPZ1n1WyrNiFK3l02Dn8BXG5YRw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risankizumab+in+Severe+Asthma+%E2%80%94+A+Phase+2a%2C+Placebo-Controlled+Trial&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Brightling%2C+Christopher+E&rft.au=Nair%2C+Parameswaran&rft.au=Cousins%2C+David+J&rft.au=Renaud%2C+Louis&rft.date=2021-10-28&rft.pub=Massachusetts+Medical+Society&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=385&rft.issue=18&rft.spage=1669&rft.epage=1679&rft_id=info:doi/10.1056%2FNEJMoa2030880&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |